A subsequent study has demonstrated that navoximod, a dual IDO1/ TDO inhibitor, induces a powerful antitumor immune response and inhibits tumor progression when combined with anti-PD-L1 antibodies [151]. This evidence concerns the gene CD274 and neoplasm.